NCT02741128View on ClinicalTrials.gov

Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

November 6, 2019

Primary Completion Date

January 19, 2023

Study Completion Date

January 19, 2023

Conditions
Dengue FeverDengue Hemorrhagic FeverHuman Immunodeficiency Virus
Interventions
BIOLOGICAL

CYD Dengue Vaccine

0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively

BIOLOGICAL

Placebo (NaCl 0.9%) vaccine group

0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively

Trial Locations (4)

59025050

Investigational Site Number :0760004, Natal

26030-380

Investigational Site Number :0760002, Nova Iguaçu

04040-002

Investigational Site Number :0760001, São Paulo

04121-000

Investigational Site Number :0760003, São Paulo

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02741128 - Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults | Biotech Hunter | Biotech Hunter